Reselute
Durham, US · Founded 2021 · Delaware corporation · 2 known investors
Reselute develops therapeutic orthopedic implants that combine structural fracture fixation with local drug delivery. Its lead technology is an intramedullary nail for tibial fractures that provides definitive internal fixation while releasing local antibiotics to help prevent infection during fracture care.
Founders & leadership
Reselute was founded in 2021 by Cambre Kelly.
CK
KG
Ken GallNamed on SEC filing
Board
AB
Andrew BeaverBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$6.7M disclosed across 4 rounds · 2023–2026
▶$1MraisedJul 2026 · 1 investors · OtherRule 506(b)
▶$1MraisedJul 2026 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Cambre KellyDirector, Executive Officer
- Andrew BeaverDirector
- Ken GallDirector
- Offering amount
- $4M
- Amount sold
- $1M
- Minimum investment
- $25K
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$2.4MraisedApr 2026 · 23 investors · OtherRule 506(b)
▶$2.4MraisedApr 2026 · 23 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Cambre KellyDirector, Executive Officer
- Andrew BeaverDirector
- Ken GallDirector
- Offering amount
- $4M
- Amount sold
- $2.4M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$2.6MraisedMay 2024 · 30 investors · OtherRule 506(b)
▶$2.6MraisedMay 2024 · 30 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Cambre KellyExecutive Officer, Director
- Offering amount
- $2.6M
- Amount sold
- $2.6M
- Minimum investment
- $10K
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$700KraisedMay 2023 · 15 investors · OtherRule 506(b)
▶$700KraisedMay 2023 · 15 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Ken GallDirector
- Cambre KellyExecutive Officer
- Offering amount
- $700K
- Amount sold
- $700K
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Reselute do?
- Reselute develops therapeutic orthopedic implants that combine structural fracture fixation with local drug delivery. Its lead technology is an intramedullary nail for tibial fractures that provides definitive internal fixation while releasing local antibiotics to help prevent infection during fracture care.
- Who founded Reselute?
- Reselute was founded by Cambre Kelly in 2021.
- Who are Reselute's investors?
- Reselute's investors include Band of Angels, Duke Capital Partners.
- How much funding has Reselute raised?
- Reselute has disclosed $6.7M raised across 4 rounds.
- Where is Reselute headquartered?
- Reselute is headquartered in Durham, US.